New Nowe: Controlled subsidiary SYS6051 Injection approved for clinical trials of drugs.

The new Norway announcement stated that the company's controlling subsidiary, Giant Stone Biotech, recently received the National Medical Products Administration's approval for the issuance of the "Notice of Approval for Drug Clinical Trial" for SYS6051, and will soon start clinical trials. SYS6051 is a targeted antibody drug conjugate against human tissue factor, with the approved indication for advanced solid tumors. However, drug research and development has high investment, high risk, long cycles and other characteristics, and there are risks such as clinical trial results not meeting expectations, but they will not have a significant impact on performance in the short term.